You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨醫藥股集體上漲,石藥集團、聯邦製藥漲超7%
港股醫藥股集體拉昇上漲,其中,石藥集團、聯邦製藥漲超7%,綠葉製藥、凱萊英、先聲藥業、康哲藥業漲超6%,信達生物、翰森製藥、中國生物製藥、麗珠醫藥跟漲。消息上,多家創新藥企業宣佈將在5月30日至6月3日舉辦的2025年美國臨牀腫瘤學會(ASCO)年會上展示創新藥物研究成果。另有分析稱,受益於三生製藥與輝瑞達成的PD-1/VEGF雙抗SSGJ-707全球權益合作的消息催化,中國創新藥企通過技術授權加速融入全球產業鏈,市場對於國產創新藥出海預期被放大。展望後市,有券商機構認爲,目前我國創新藥進入成果兌現階段,研發進展催化較多,有望持續作爲2025年醫藥板塊投資主線。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.